ICVX’s lead program is a combination vaccine for RSV and hMPV that AZN says is ready to go into phase-3 trials. The nominal deal value (excluding the CVR) is $800M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.